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The multimorbidity interaction severity index (MISI)
A proof of concept study
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Abstract
Therapeutic decision-making for patients with multimorbidity (MM) is challenging. Clinical practice guidelines inadequately address
harmful interactions and resulting therapeutic conﬂicts within and among diseases. A patient-speciﬁc measure of MM severity that
takes account of this conﬂict is needed.
As a proof of concept, we evaluated whether the new Multimorbidity Interaction Severity Index (MISI) could be used to reliably
differentiate patients in terms of lower versus higher potential for harmful interactions.
Two hypothetical patient cases were generated, each with 6 concurrent morbidities. One case had a low (i.e., low conﬂict case)
and the other a high (i.e., high conﬂict case) potential for harmful interactions. All possible interactions between conditions and
treatments were extracted from each case’s record into a multimorbidity interaction matrix. Experienced general internists (N=18)
judged each interaction in the matrix in terms of likely resource utilization needed to manage the interaction. Based on these
judgements, a composite index of MM interaction severity, that is, the MISI, was generated for each physician and case.
The difference between each physician’s MISI score for the 2 cases (MISIdiff) was computed. Based on MISIdiff, the high conﬂict
case was judged to be of signiﬁcantly greater MM severity than was the low conﬂict case. The positive values of the inter-quartile
range, ameasure of variation (or disagreement) between the 2 cases, indicated general consistency of individual physicians in judging
MM severity.
The data indicate that the MISI can be used to reliably differentiate hypothetical multimorbid patients in terms of lesser versus
greater severity of potentially harmful interactive effects. On this basis, the MISI will be further developed for use in patient-speciﬁc
assessment and management of MM. The clinical relevance of the MISI as an alternative approach to deﬁning MM severity is
discussed.
Abbreviations: CSS = cascading style sheets, DDI = disease–disease, drug–disease, and drug–drug interactions, DG = Dimitri
Gassmann, EB = Edouard Battegay, HTML = Hypertext Markup Language, MISI = multimorbidity interaction severity index, MM =
multimorbidity.
Keywords: computerized decision support, drug–disease interactions, drug–drug interactions, MISI, multimorbidity, severity
index, therapeutic conﬂict
1. Introduction
Multimorbidity (MM) refers to the presence of multiple
concurrent acute or chronic diseases within a person.[1,2]
Therapeutic decision making for multimorbid patients is
challenging.[3–6] This is because decisions rely on recommenda-
tions from clinical practice guidelines that were developed for the
treatment of single diseases.[7–9] With some exceptions,[9–12]
these guidelines are based on evidence from studies that excluded
or under-represented multimorbid cases.[13–16] This mono-
morbid approach to therapeutic decision-making in MM does
not, therefore, adequately address the combined impact of
potentially harmful disease–disease, drug–disease, and drug–
drug interactions (DDIs) and multiple drug regimens[9,17–21]
or adequately guide the clinical decision-maker through the
therapeutic conﬂict.
Therapeutic decision making in MM requires consideration of
potential DDIs[22,23] and their combined impact to determine
a suitable clinical strategy, on a case-by-case basis. In some
patients, co-occurring conditions and treatments can be managed
without risk of harmful effects (e.g., physical exercise for
hypertension, diabetes, and dyslipidemia) due to the treatment
of one of the constituent conditions. But therapeutic conﬂict of
various degrees of severity is typically encountered in that the
treatment for 1 condition is contraindicated by the presence of
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1 or more other conditions or treatments.[24] This applies, for
instance, to concurrent gastrointestinal bleeding and anticoagu-
lant treatment for heart disease, concurrent severe lung disease
and benzodiazepine treatment for a sleeping disorder, or severe
lung disease and opiate treatment for a pain disorder.[8,25] The
overall complexity of such cases can place particularly high
demands on the clinical decision-maker in reconciling the range
of harmful interactions with a therapeutic strategy that is
speciﬁcally tailored to the particular needs of the patient.[26,27]
Intensive work to support clinical decision making in MM is in
progress (e.g.,[9,11,13,28]). But, at present, there is no instrument for
measuring patient-speciﬁc burden of harmful DDIs that can be
applied to any combination of medical conditions. A reliable
measure of MM burden would facilitate the development of tools
and guidance to support diagnostic and therapeutic decision
making and provide a valuable frame of reference for comparing
research ﬁndings (e.g.,[29]). The most commonly applied measures
in the ﬁeld of MM were originally constructed to support clinical
decisionmaking in speciﬁc patient groups in hospital settings or for
research purposes (e.g.,[30–34]). These measures typically quantify
the degree of MM in an individual by summing the number of
concurrent diseases. Given the limitations of this approach, these
measures havebeen superseded in part by the use of indices. Indices
use weights to differentially assess each disease or condition, for
instance, in terms of the physician’s judgement of likely severity or
resource utilization[35–39] or prognosis.[40] While this approach is
considered useful for informing the planning and prioritization of
treatment,[41] a complex case can render assessment particularly
difﬁcult.
We developed therefore a web-based decision support tool for
use at patient encounter to facilitate assessment of complex cases
and therapeutic decision making. The tool has 3 main features.
First, it generates a case-speciﬁc multimorbidity interactionmatrix
of all potential DDIs from the patient record. Thematrix is used to
score eachDDI in terms of likely resource utilization (i.e., expected
intensityof effort needed tomanage the interaction) and is intended
to aid the physician’s consideration of harmful DDIs and points of
caution, uncertainty, andpriority in the clinicalmanagement of the
speciﬁc case. Second, the tool generates a networkgraph fromthese
scores to help the physician visualize his or her assessment of the
case (see Fig. 1). Third, the tool generates an overall composite
score, or multimorbidity interaction severity index (MISI), of the
case as a summary evaluation of the interaction severity of the case
on a comparative scale. This preliminary study used the MISI as a
basis for the initial evaluationof the tool.We tested the expectation
that the MISI could be used to reliably differentiate 2 hypothetical
multimorbid patient cases in terms of potential lower versus higher
therapeutic conﬂict. Each case comprised a cluster of 6 similar
concurrent conditions, in 1 case with a low and in the other a high
potential for harmful interactions and therapeutic conﬂict.
2. Methods
2.1. Participants
Eighteen senior physicians (8 females, mean years of clinical
experience as General Internists = 12.94, SD = 6) volunteered to
participate. All participants were senior General Internists and
staff members of the Department of Internal Medicine (General
Internal Medicine), University Hospital of Zurich, Switzerland
and native or ﬂuent speakers of Swiss German (or Standard
German) and ﬂuent speakers of English. This pilot study was
designed to explore the new index of MM severity on the basis of
different patterns of responses of the participants in judging the
severity of patients DDIs in terms of expected resource utilization.
In the absence of comparable data for the application of this
Figure 1. Network graph generated from the multimorbidity interaction matrix on the basis of the participants’ ratings of interaction severity, showing (A) the graph
for the low conﬂict case with little risk of harmful interactions, and (B) the graph for the high conﬂict case with a high risk of harmful interactions.
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construct to all combinations of potential DDIs, the sample size
was selected on the basis of the experience gained developing the
MISI. Sample size calculations for future development of theMISI
can be based on estimates derived from this study. Local ethics
committee approval was not required for the purpose of our
sample of physicians evaluating hypothetical patients. Written
informed consent was obtained according to the guidelines of the
Declaration of Helsinki, data coded anonymously, and each
physician debriefed at the end of the study. The data used and
analyzed for the current study are available from the corre-
sponding author on reasonable request.
2.2. Materials
2.2.1. Hypothetical patients. Authors EB and DG generated 2
hypothetical clinically plausible patient cases, a low and a high
conﬂict case, each with 6 concurrent morbidities. In the low
conﬂict case, the selection of concurrent conditions and treat-
ments was deemed to have a low risk of harmful interactive
effects and therapeutic conﬂict, whereas in the high conﬂict case
these were considered to carry a high risk of harmful interactive
effects and therapeutic conﬂict (see Table 1). The data of
diagnosed conditions and medications of the hypothetical cases
were imported into the web-based MISI.
2.2.2. Technical description of the web-based MISI. The
MISI is integrated into a web-based decision support tool. The
tool comprises a platform-independent, web browser-based
system, with a graphical user interface and a dedicated server
component. It is built on open source technology, including node.
js andMongoDB for server-side application (express.js, passport.
js, mongoose.js, socket.io) and HTML, CSS, and various
JavaScript libraries (angular.js, d3.js, and Twitter Bootstrap)
for the browser client.
2.3. Study procedure
All participants were tested individually in a small quiet room,
located at the University Hospital of Zurich, and were blind to
the design of the hypothetical cases. The experiment lasted
approximately 35min. The 2 cases were presented across
participants in counter-balanced order. The experimental setup
included a 13-inch MacBook Pro with a Retina display and an
optical mouse. The server of the web-based tool operated on the
machine locally, with the webapp displayed in Firefox v42.0 in
full-screen mode. Participants provided demographic informa-
tion (e.g., age, clinical experience as General Internists). The web-
based MISI was then presented to the participants. It was
explained how to use the MISI and ensured that the explanation
had been understood.
Each participant subsequently read the written instructions
presented on the PC monitor as to how to proceed. First, and
using the web-based MISI, a panel displayed information on the
hypothetical case (e.g., the reason for the encounter, relevant
ﬁndings in clinical examination, further relevant ﬁndings in
diagnostic tests, medical history). Second, the hypothetical list of
conditions and medications was displayed and the participants
were required to rate each condition as either active or inactive
and each medication as either modiﬁed or unmodiﬁed. The
web-based MISI provides a deﬁnition of active and modiﬁed:
Active is anymedical condition that requires current and ongoing
diagnostic or therapeutic (pharmacological or other) attention
or measures, and modiﬁed is any medication or other
therapeutic measure that needs to be altered in content or
dose. These and all further ratings were conducted by mouse
click on the checkboxes of the MISI’s interface. Third, upon
completing the last step, the MISI automatically generated a
panel displaying a multimorbidity interaction matrix of all
possible interaction pairs extracted from the list of active
conditions and medications. Participants were required to rate
each interaction pair on a qualitative 4-point severity scale of
resource utilization (i.e., expected intensity of effort needed to
manage the interaction). The scale ranges from “not harmful”
(requiring therefore no action) to “life threatening” (requiring
therefore severe action), as shown in Table 2. The severity scale
also included a further option “don’t know” to indicate that the
participant is unable to judge whether a potential interaction
might be harmful.
Finally, after completing the multimorbidity interaction
matrix, the composite MM severity score was computed
automatically and displayed above the matrix. The composite
score of theMISI is computed by summing up the total number of
conditions, medications, active conditions, modiﬁedmedications,
and the number of all interactions rated in terms of severity as
minor, as major (multiplied by 3), and as life threatening
(multiplied by 10) (see Table 3). Upon completion of the test, the
participant was debriefed and asked to report any difﬁculties
experienced using the web-based MISI.
To aid decision-making, the web-based decision support tool
also generates a visually intuitive network graph to represent
the internist’s judgements of interaction severity, as rated in
the multimorbidity interaction matrix (see Fig. 1). The graph
provides a visual impression of the overall MM severity of the
case. The aim of this visualization is to support the physician by
highlighting nontrivial relationships that might otherwise be
overseen in the complex patient by showing the relevant
interactions between the conditions and treatments weighted
according to the internist’s judgements of severity. MM severity
of each case can be visualized in network graph generated from
the multimorbidity interaction matrix (see Fig. 1).
3. Results
All data analyses were performed using SPSS version 21.0 (SPSS
Inc, Chicago, IL). There were no missing data.
Table 1
Conditions and medications of 2 hypothetical patient cases.
Hypothetical patients Conditions Medications
High conﬂict case Hypertensive emergency Lisinopril
Renal failure Nitroglycerin
Diabetes Mellitus type II Metformin
Depression Escitalopram Prednisone
Rheumatoid arthritis Morphine
Chronic alcohol abuse
Low conﬂict case Iron deﬁciency anemia Ferrous sulfate
Diabetes mellitus type II Metformin
Panic disorder Lorazepam
Arterial hypertension Lisinopril
Gastritis Type C Esomeprazole
Hypothyroidism Levothyroxine
The conditions in the left column are shown in relation to the corresponding medications to treat the
conditions in the right column. The interactions in the low conﬂict case were designed to have a low
risk of harmful interactive effects and those of the high conﬂict case to have a high risk of harmful
interactive effects.
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One might anticipate that the high conﬂict case demands more
careful consideration in making judgements about potential
harmful interactions and resource allocation than does the low
conﬂict case and that greater consideration is reﬂected in the time
taken to judge each case. In fact, the mean time taken by the
internists to score the interactions in the MISI’s multimorbidity
interaction matrix wasM=11.58min (SD=4.21; range = 3.25–
21.48) for the low conﬂict case and M=15.76min (SD=4.99;
range = 5.27–24.37) for the high conﬂict case. A paired t test
showed that the high conﬂict case took signiﬁcantly longer to
score than the low conﬂict case, t(17)= 4.53, P<0.001.
Each patient case was designed to have 6 generally relevant
medical conditions and medications. Before using the multi-
morbidity interaction matrix to rate each potential DDI in terms
of likely resource allocation, the internists were ﬁrst required to
judge whether each condition was currently active and whether
the medication used needed to be modiﬁed. Before testing for
differences between the 2 hypothetical cases, the Kolmogorov–
Smirnov test for normality was conducted.[42] This indicated that
the distribution of active condition judgements deviated
signiﬁcantly from a normal distribution in the low (D= .298,
P<0.01) and high conﬂict case (D= .274, P<0.01). AWilcoxon
Signed-ranks test was therefore applied,[43] this showing no
signiﬁcant difference between the high (Mdn=5) and low conﬂict
case (Mdn=6) in terms of active judgements,Z=0.78, p=0.44.
The Kolmogorov–Smirnov test for normality indicated that the
distribution of modiﬁed medication judgements also deviated
signiﬁcantly from a normal distribution for the low (D=0.226,
P= .02) but not for the high conﬂict case (D=0.177, P=0.14). A
Wilcoxon Signed-ranks test was therefore performed. This
showed that the high conﬂict case (Mdn=3.5) was judged as
requiring modiﬁcation signiﬁcantly more often than the low
conﬂict case (Mdn=1), Z=2.37, P=0.018.
In other words, the preceding analyses show that the internists
judged no difference between the 2 cases in terms of the number
of active concurrent conditions. But they did judge a difference
in terms of the number of required medication modiﬁcations.
Given the same number of conditions in each case, the results
suggest that the cumulative number of concurrent conditions
or conditions (i.e., the oft used deﬁnition of MM) does not
necessarily reﬂect the clinical resource effort needed to manage
(i.e., in this case, to modify medications) in a multimorbid
patient.
We then evaluated whether the MISI could be used to reliably
differentiate between the 2 patient cases in terms of lower versus
higher therapeutic conﬂict. To do this, the difference between
each physician’s composite MM severity score, MISIdiff, was
computed and used for further analyses.
The descriptive data for MISIdiff largely show positive
values (Min= -5, 1stQuartile=16.75, Mdn=32.50, M=30.44,
3rdQuartile=47.75, Max=64.00). This means that most raters
gave the low conﬂict case a lower score than the high conﬂict case.
In fact, the mean 50% of internists produced a MISIdiff value
between 16.75 and 47.75 between the 2 cases. The positive values
of the inter-quartile-range (IQR=31) and the standard deviation
(SD=19.84) for MISIdiff, used as measures of variation (or
disagreement) between the 2 cases, suggest overall consistency
of the individual physicians in their judgments. However, the
minimum value of5 indicates that at least 1 physician rated the
low conﬂict case as having slightly greater MM severity than
the high conﬂict case.
For illustrative purposes,MISIdiff can be shown in a scatter plot
based on the Bland–Altman (B&A) approach[43] (see Fig. 2). The
scatter plot allows the pattern of MISI data to be inspected: each
point in the plot shows the mean of each physician’sMM severity
scores for cases 1 and 2 on the X-axis and each physician’s
MISIdiff for cases 1 and 2 on the Y-axis. The overall mean of
MISIdiff across all physicians is M=30.44 (SD=19.83). Closer
inspection of Fig. 2 reveals that 2 of the 18 physicians show
differences in their MM severity scores of close to zero, meaning
Table 2
The table shows the 4-point severity rating scale, with a corresponding description and example (condition andmedications) for each level
of severity.
Severity rating scale Description Example: Oral anticoagulation drugs and git-bleeding
Don’t know Cannot be judged due to a lack of knowledge Gastritis 5 years ago and ongoing oral anti- coagulations drugs
Not harmful Requires no action Gastroenteritis with stomach ache and oral anti- coagulation drugs
Minor Requires moderate action Duodenal angiodysplasia and ongoing oral anti- coagulation drugs
Major Requires intense action Gastric ulcer with a relevant anaemia and ongoing oral anticoagulation drugs
Life threatening Requires full action Bleeding from varices and ongoing oral anti-coagulation drugs
The scale ranges from ”not harmful” to ”life threatening” interaction. The option ”don’t know” is also given to indicate lack of appropriate knowledge to judge the potential interaction.
Table 3
The table shows an example of the composition of theMISI on the basis of one of the participant’s ratings of a low and a high conﬂict case.
MISI composition Low conﬂict case High conﬂict case
General relevance Number of conditions 6 6
Number of medications 6 6
Current relevance Active conditions 5 4
Modiﬁed medications 0 5
Harmful DDIs
∗
Severity ratings of individual DDIs 10 38
MISI Overall impact of DDIs 27 59
The MISI is computed by summing up the total number of conditions, medications, active conditions, modiﬁed medications, and the number of all interactions. The interactions were rated in terms of severity as
minor, as major (multiplied by 3), and as life threatening (multiplied by 10). The result in this participant’s example is MISI=27 for the low conﬂict case (with little risk of harmful interactions) and MISI=59 for the
high conﬂict case (with a high risk of harmful interactions).
∗
DDI=disease–disease, drug–disease, and drug–drug interactions. MISI=multimorbidity interaction severity index.
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that these 2 judged theMM severity of the 2 cases as being highly
similar.
The Kolmogorov–Smirnov test for normality indicated that the
MISIdiff distribution did not deviate signiﬁcantly from a normal
distribution (D=0.122, P=0.200). A one sample t test was
conducted to test the null-hypothesis that MISIdiff is zero, that is,
the physicians judged the 2 cases similarly in MM severity. This
test showed that the difference between the MISIdiff values (M=
30.44, SD=19.83) and zero was highly signiﬁcant, t(17)=6.51,
P<0.001, 95% CI 20.58, 40.31. This indicates that the
physicians distinguished between each case in terms of lower
and higher MM severity and therapeutic conﬂict.
4. Discussion
As a proof of concept, the present study evaluated whether the
MISI could be used to reliably distinguish between 2 clinically
relevant but hypothetical patient cases in terms of the intensity of
effort (i.e., resource utilization) required to clinically manage
harmful interactions. The 2 patients were designed to have either
a low or high risk of harmful interactive effects with a
corresponding degree of therapeutic conﬂict (see Table 1). In
the high conﬂict case, the design included hypertensive
emergency, renal failure, and diabetes mellitus type II as a
typical cluster of conditions in MM.[44] Depression, often
associated with noncompliance, may cooccur with these
conditions, and noncompliance may be associated with hyper-
tensive emergencies.[44–46] Diseases such as rheumatoid arthritis
can cooccur with the other conditions, though not necessarily in
relation to the typical cluster.[47] In the low conﬂict case, these
prevalent diseases (iron deﬁciency anemia, diabetes mellitus type
II, panic disorder, arterial hypertension, gastritis type C) often
cooccur, with the exception of hypothyroidism, but not as a
typical MM cluster.[48–50] Consistent with their design, the
analyses showed that the low conﬂict case was judged to be of
signiﬁcantly less MM severity than the high conﬂict case. The
data thus support the use of theMISI as a means to distinguishing
between different patient cases in terms of the severity of harmful
interactions and therapeutic conﬂict.
This web-based tool is novel both as an instrument and for
physicians who have never used a multimorbidity severity matrix
to judge harmful interactions, as in our case. In this sense, the
physicians were also under investigation. As a precursor to a
conventional inter-rater agreement analysis, in which we would
have a larger range of hypothetical or real cases (e.g.,[51]), this
preliminary study was designed to give insight into the pattern of
MISI data generated by the physicians while applying careful
experimental control to the 2 cases. The general difference in the
pattern of MISI data between the cases suggests that the
physicians similarly understood and used the multimorbidity
severity matrix to judge expected resource utilization. While this
suggestion is supported by the physicians’ feedback at debrieﬁng,
we are mindful of potential sources of error in our new approach.
We consider therefore the present study in terms of a number
of factors that require more attention before conducting a
conventional study of inter-rater agreement.
This tool is intended for use as a brief instrument to facilitate
assessment of complex cases and illness severity. The time taken
for our experienced general internists (who received only a brief
introduction to the tool) to complete their task averaged 12
minutes for the low conﬂict case and 16minutes for the high
conﬂict case. This difference likely reﬂects a greater level of
difﬁculty in assessing the high conﬂict case, but there was large
variability between internists. This ranged from 3 to 24minutes.
This variability might suggest potential for improving the time to
administer the instrument. Multiple factors, including uncer-
tainties in MM and differences in internists’ knowledge and
experience, inﬂuence the process of evaluating the complex
multimorbid patient and this is likely to reveal differences
between clinical decision makers[52,53] in terms of completion
time and the absolute values of the MISI.[54–56]
While the internists were all highly experienced in MM, they
were not trained in or otherwise accustomed to using a
multimorbidity interaction matrix to score harmful interactions.
Training would help to ensure a common understanding of the
matrix and its scoring procedure and enhance agreement between
the physicians.[57,58] To develop a common understanding
(referred to in rater training as a frame of reference, e.g.,[59])
potential sources of disagreement between users of this tool need
to be identiﬁed.[60] A primary consideration in the present study is
the extent to which the descriptors used to characterize the
severity scale (see Table 2) are open to discrepant interpretation
by different internists. Severity was operationally deﬁned in terms
of internists’ subjective judgements of projected resource
utilization (i.e., intensity of effort) to manage harmful inter-
actions. At debrieﬁng, this deﬁnition was not reported as
presenting any difﬁculties, and the inter-quartile-range, used as a
measure of variation (or disagreement) between the 2 cases,
suggests general consistency (albeit with the exception of
3 internists) in the use of the severity scales across the 2 cases
(cf.[61]).
It is possible that good consistency (or, in a study with more
than 2 patient cases, good interrater agreement) within a single-
center sample reﬂects a good degree of shared knowledge of and
routine in applying available center-speciﬁc resource and care
management procedures. Any differences across centers in
resources and procedures for MM in general or for speciﬁc
clusters of MM might have a different inﬂuence on physicians’
judgements of resource utilization for the treatment of MM
patients. This might result therefore in some degree of systematic
variation in inter-rater agreement across centers. As a broadly
applicable measure, the MISI might provide a means to
Figure 2. The scatter plot (based on the Bland–Altman approach) depicts the
mean of a particular physician’s 2 MM severity scores for cases 1 and 2 on the
X-axis and the difference between that physician’s 2 MM severity scores for
cases 1 and 2 (i.e., high conﬂict case minus the low conﬂict case, or MISIdiff) on
the Y-axis. The mean overall mean difference between cases 1 and 2 across all
physicians is M=30.44 (SD=19.83).
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evaluating this possibility. But the present study revealed that 2 of
the physicians judged the low conﬂict case as slightly more severe
than the high conﬂict case. Besides training, knowledge, and
experience, testing is needed to establish what other (e.g.,
motivational) factors might inﬂuence the use of the tool for
judging MM severity.
These factors might include experimental considerations.
Every effort was made during recruitment and at instruction
to ensure that participants were not aware of any potential
difference in the severity of the hypothetical cases. Once
physicians began using the multimorbidity severity matrix to
rate the expected resource utilization of potentially harmful
interactions, the physician may have tried to infer from those
ratings the general severity of the case. The motivation behind
using a multimorbidity severity matrix is that it might make it
easier to build up a picture of a more complex case. This might be
particularly helpful for less experienced physicians. But from an
experimental perspective, we cannot exclude the possibility that a
physician’s ratings inﬂuenced subsequent ratings in the matrix,
or that the severity ratings were biased by the physician’s
anticipation of the general severity of the case before completing
the matrix. While we ensured that conditions and medications
were always presented in the same sequence across all
participants, future experiments could randomize the order of
entries in the matrix to test for such bias. On the other hand, the
network graph and the ﬁnal index were only accessible to the
physician after the completion of the matrix and did not inﬂuence
the physician’s ratings.
The strengths and weaknesses of the web-based tool may be
considered in relation to its main features. The multimorbidity
interaction matrix may help the physician to build up a cohesive
and systematic assessment of potentially harmful DDIs. This can
be important because, unlike the well-structured reporting of
diagnoses and conditions, interactions are often described,
sometimes lengthily, in free text. Given the potential complexity
of many cases, the matrix might be especially helpful for less
experienced physicians. To ensure the relevance of the judge-
ments of resource allocation as a basis for using the matrix and
determining severity of DDIs, these judgements need to be
evaluated in relation to outcome measures such as hospital stay,
morbidity, mortality, and resource use. A major weakness of the
present matrix is that it requires manual work. Future
development aims to simply its use and usability by, for instance,
integrating a database query of DDIs and data from an expert
panel to automatically highlight likely and relevant DDIs for a
givenMM cluster. A limitation at present is that all diagnoses in a
database query of DDIs must be encoded or structured in a way
that can be further processed by the web-based tool. This is not
yet the case.
The main strength of the network graph is that it allows the
user to visualize severity of interactions at one glance. Especially
in a complex case, a simple visual overview of the pattern of DDIs
might reduce the cognitive load of maintaining a mental
representation of DDIs (see Fig. 1B).[62] A further advantage is
that the visual representation highlights the interactions accord-
ing to the physician’s own judgements of severity, making the
network graph immediately relevant for the physician and the
case. Potentially, the graph could augment the reporting of
complex cases as ameans to gaining a quick overview of the DDIs
in a case and by highlighting potentially critical points of
convergence between conditions and medications that require
might particular attention. The graph cannot replace clinical
contact to the patient. Empirical evaluation of the usability and
effectiveness of the network graph for less and more experienced
internists as a simple aid to representing, communicating and
considering a complex case awaits investigation.
As a summary measure, the MISI may be used to gauge and
communicate the general severity of a case. Importantly, theMISI
provides a summary evaluation of the harmful interactions at a
given point in time. As a momentary assessment, the value of the
MISI will change over the course of treatment. With further
development, the use of the MISI as a basis for measuring change
in interaction severity over time will be tested. One priority for
further development is to ﬁrst ensure the reliability of this index.
The index might then be used as a reference for typical MM
clusters (and combinations of harmful DDIs), as established for
example by an expert panel. The advantage of this is that a
physician could judge his or her assessment of case severity
against the reference. While the MISI is conceptualized as a
comparative scale, empirically based thresholds of higher,
medium, and lower risk are needed. These thresholds are likely
to be time-consuming and costly to develop, but they would
foster for purpose of research and clinical assessment consistent
and meaningful interpretation within particular and across
different MM clusters.
To consider potential strengths and limitations from the
perspective of the user, we collected feedback from the physicians
at debrieﬁng. This supported the view that the matrix evoked
greater reﬂection about and awareness of potential DDIs and
therapeutic conﬂict. The network graph was not investigated, but
the feedback supported the idea that the visualization could help
to make the user more aware of these interactions and conﬂicts.
On the other hand, the use of the matrix was reported by some as
requiring a high level of attention. The task of explicitly judging
the severity of DDIs generated a sense of uncertainty in some
raters, in part because it revealed to the rater imperfect
knowledge: internet links to an interaction checker were
suggested. Clearly, the task was made more difﬁcult in this
study by the fact that anamnestic, clinical, and laboratory data
were not provided.
The data of this study show that quantifying the degree ofMM
simply on the basis of the cumulative number of concurrent
conditions does not necessarily reﬂect the clinical effort needed to
prioritize, plan, andmanage harmful interactions. As indicated in
Table 3 and Fig. 3, the total number of a patient’s conditions and
medications can deviate from the number of conditions and
medications that the physician considered to be relevant for
current treatment.While each patient case was designed to have 6
concurrent conditions, the analyses showed a signiﬁcant
Figure 3. The ﬁgure illustrates the composition of the MISI, based on one
physician’s ratings of a low conﬂict case (right side of main panel) and a high
conﬂict case (left side of main panel).
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difference between the low conﬂict and high conﬂict cases
in terms of the judged need to modify the patient’s medications;
the high conﬂict case requiring a signiﬁcantly greater number of
modiﬁcations. The physician must also prioritize the clinical
effort needed to manage and monitor more harmful interactions.
The computation of theMISI considers, therefore, the cumulative
number of concurrent conditions and medications, while
weighing the index to take account of more severe DDIs that
the physician considers to require more urgent attention. Further
work is needed to ensure that the judgments of anticipated
resource utilization and our weighting procedure reasonably
reﬂect real resource utilization.
Other indicators of MM severity have been used.[40] These
range from composite measures based on multiple dimensions
(e.g., prognostic threat to life, number of organs affected,
disability, complications, and seriousness of treatment) to more
simple uni-dimensional measures of severity.[63,64] The MISI
could be easily adapted to generate a composite score based on
1 or more other such dimensions. But the present deﬁnition of
severity, in terms of resource utilization, serves to focus attention
on the relationship between the use of health care resources and
DDIs[42] by considering the immediate relevance of the variously
harmful interactions for clinical prioritization, planning, and
management.[65] This is important considering the impact of
MM on health service utilization and costs.[66–68] These costs
increase exponentially with the increasing number of chronic
diseases.[69]
5. Conclusion
The present study demonstrated that the MISI can be used as a
measure of subjective judgement of harmful interactions to
reliably distinguish between 2 hypothetic patients of potentially
low and high therapeutic conﬂict. The judgement of harmful
interaction is based on the internist’s subjective assessment of the
intensity of effort (i.e., resource utilization) required to clinically
manage the harmful interactions. In conducting this proof of
concept study, we made the assumption that the main source of
systematic variation in the subjective judgements of resource
allocation would be attributable to the differences in DDIs
between the low and high conﬂict cases. But the impact of
the internists’ expertise in treating MM and the validity of the
subjective construct “resource utilization” itself needs to be
subject to testing. Importantly, theMISI needs to be evaluated for
a larger number of patients and for a greater range of variously
severe MM. In supporting clinical decision making, the patient-
speciﬁc MISI focuses attention on the patient as a whole, rather
than on any 1 multimorbid condition, by highlighting the
interacting conditions and treatments (cf.[70]). The visually
intuitive network graph is designed to help the clinical
decision-maker visualize his or her assessment of the case. The
potential usability and effectiveness of the graph as an aid to
representing, communicating, and considering a complex case
awaits evaluation. The digital format of the MISI means that this
instrument is practical to administer and easy to adapt for
application in clinical practice and research.
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